A role for dendritic cells (DCs) has been emphasized in the onset of acute graft-versus-host disease (GVHD). We have made efforts to develop a new strategy for suppression of DC functions with a chemical compound in the treatment of acute GVHD. We here describe the immunological characterization of the new chemical compound NK026680. It was found that NK026680 significantly suppressed (1) expression of CD83, CD86, and major histocompatibility complex (MHC) class I and II antigens on human monocyte-derived DCs, (2) excretion of interleukin-12p40 on activation of monocyte-derived DCs, (3) allogeneic responses of human and mouse T cells and (4) mortality in mice with acute GVHD evoked across MHC class I or II. The beneficial effect of NK026680 administered orally was without any recognizable adverse effects. Early intervention in acute GVHD was required for this effect, indicating that an early event in acute GVHD is a critical target of NK026680. We propose the use of NK026680 as a prophylactic for acute GVHD.
Introduction
The transplantation of allogeneic hematopoietic stem cells is a curative approach to the treatment of hematopoietic disorders including malignant lymphomas, leukemias, autoimmune diseases and congenital immunodeficiencies. However, graft-versus-host disease (GVHD) has been a major cause of post transplant morbidity and mortality.
Thus, the prophylaxis and treatment of GVHD are of primary importance for successful allogeneic hematopoietic cell transplantation. Acute GVHD is known especially to influence the recipient's condition. It is known that acute GVHD develops as a consequence of an allogeneic immune response, where donor T cells interact with host dendritic cells (DCs) at the first recognition stage. [1] [2] [3] Then, allogeneic donor T cells primarily recognize major histocompatibility complex (MHC) antigens on host DCs, and subsequently activate and proliferate in the presence of DC-derived accessory signals and cytokines. Currently proposed or practiced prophylaxis for acute GVHD includes use of a monoclonal antibody to CD52, 4 CD25, 5, 6 cytotoxic T-lymphocyte antigen-4 7 or tumor necrosis factor-alpha (TNFa) 8 all of which are DC-specific antigens and/or take part in T-cell activation in the antigen presentation stage. Currently increasing studies for the development of immunosuppressive drugs have been evaluating DC function as a pharmacological target for prevention of acute GVHD. 9 To develop a new pharmacological approach to the prevention of acute GVHD by suppressing DC function in vivo, we screened a large number of synthetic chemical compounds with suppressive activity toward TNFa-dependent MHC class I augmentation on human monocytederived dendritic cells (MoDCs). Eventually, the compound NK026680 was found to be the most potent inhibitor of MHC class I expression on MoDCs with little cytotoxicity in culture. Here, we describe the immunological characterization of NK026680. Our data provide evidence that NK026680 suppresses the increase in protein expression associated with DC function, and works as a highly active immunosuppressant for prevention of acute lethal GVHD in the mouse, without any recognizable toxic effect. We discuss the significance of DC activation in the early phase of acute GVHD and the mode of action of NK026680 in vivo. ) were purchased from Jackson Laboratory, Bar Harbor, ME, USA. All mice were maintained under specific pathogen-free conditions at Nippon Kayaku Co., Ltd, Tokyo, Japan. Animal care and experiments were conducted according to national and international laws and policies, and permitted by local governmental authorities.
Materials and methods

Mice
Agents
The chemical compound, NK026680, was synthesized at Nippon Kayaku Co., Ltd. NK026680 was dissolved in 0.1% dimethylsulfoxide-containing culture medium for in vitro assay, or suspended in 0.5% carboxymethylcellulose at a concentration of 0.5 or 2 mg/ml for oral administration to mice. These preparations were kept at À201C until used. Cyclosporine A (CsA) was purchased from Novartis Pharma Co. Ltd, Basel, Switzerland. CsA was diluted in olive oil and orally administered to mice.
Isolation of MoDCs and T cells from human peripheral blood
Human MoDCs were prepared as described previously. 10, 11 Briefly, CD14-positive and -negative cells were separated from the peripheral blood of healthy volunteers with anti-CD14 monoclonal antibody-labeled microbeads and a magnetic cell separation system (Miltenyi Biotec, Alburn, CA, USA). After the removal of non-adherent CD14-positive cells by short-term culture, adherent CD14-positive cells were further cultured in DC culture medium for 7 days. DC culture medium was made from RPMI1640 medium supplemented with 10% fetal calf serum, 50 ng/ml of recombinant granulocyte/macrophage colony-stimulating factor (GM-CSF) (PeproTech, Rocky Hill, NJ, USA) and 50 ng/ml of interleukin (IL)-4 (PeproTech). Non-adherent cells after 7 days of culture were used as immature MoDCs. Maturation of MoDCs was facilitated by further culturing in DC culture medium containing 50 U/ml of TNFa for 3 days. MoDCs were treated with NK026680 during this maturation process. T cells were separated from CD14-negative cells with further purification on nylon fiber columns (Wako Ltd, Osaka, Japan). T cells were stored in a Cell Banker (Zenyaku Kogyo, Tokyo, Japan) at À801C before use. Cell viability was estimated with the Trypan blue dye exclusion method.
Flow cytometric analysis
Antibodies to human antigens, including MHC class I, MHC class II (Immunotech, Marseille, France), CD1a, CD40, CD54, CD80, CD83 and CD86 (PharMingen, San Diego, CA, USA), were purchased for immunostaining. MoDCs were incubated with the fluorescence-conjugated antibody at 41C for an hour, washed with PBS and then suspended in PBS containing 5 mg/ml of propidium iodide (PI). The expression of antigen was analyzed with the Cellquest software of FACScan (Becton-Dickinson, Franklin Lakes, NJ, USA). Dead cells positive for high PI staining were eliminated from data collection.
Cytokine measurements
The amount of human IL-12p40 or human IL-10 in the supernatant was measured with an enzyme-linked immunosorbent assay (ELISA) kit (Biosource International, Camarillo, CA, USA). Absorbance at 450 nm was measured with a microplate spectrophotometer, Benchmark Plus (Bio-Rad, Richmond, CA, USA). Induction and evaluation of acute GVHD Acute GVHD in mice developed according to the methods described previously. 12, 13 Briefly, CD4 þ or CD8 þ T cells were prepared from donor spleen cells by magnetic cell separation with anti-mouse CD4 or anti-mouse CD8a antibody (Miltenyi Biotech). The purified cells were suspended in Hank's balanced buffered saline (GIBCO BRL, Rockville, MD, USA), and 1.25 Â 10 5 cells were injected via a tail vein into a sublethally irradiated recipient mouse (6.0 Gy) at day 0. NK026680 (5 or 20 mg/kg once daily p.o.) was administered from day À1 to 18 (total 100 or 400 mg/kg). CsA (50 mg/kg once daily p.o.) was given from day À1 to 12 (total 700 mg/kg). The onset of acute GVHD was monitored based on body weight loss and survival.
Measurement of T-cell proliferation
Statistical analyses
Differences in the amount of IL-12p40 excretion, the survival rate and the body weight loss were statistically evaluated with the parametric Dunnett test, the log-rank test and multiple comparison by period, respectively. We regarded Po0.05 as significant.
Results
Chemical properties, toxicity and bioavailability of NK026680 NK026680 was discovered among derivatives of [1, 2, 4] triazolo [1,5-a] pyrimidine by screening of our sample collection. Its chemical structure was defined to be (S)-( þ )-1- (Figure 1) . The other derivatives also showed immunosuppressive activity, but to a lesser extent (data not shown).
Genotoxicity of NK026880 was negative in the umu-test at 5 mg/ml and in the rat micronucleus test at a single dose of 500 mg/kg p.o. (data not shown). None of the NK026680-treated groups showed symptoms of biotoxicity such as body weight loss, incidence of infection and histopathological damage of liver, gallbladder, pancreas, kidney, small intestine and large intestine. In mice treated with a single dose of 3 mg/kg p.o., the maximal plasma concentration (C max ) of NK026680 was 1280 nM 10 min post dose, the terminal half-life (T1/2z) was 2.4 h and bioavailability was estimated as 50.9% (data not shown).
Effect of NK026680 on the maturation-related changes to human DCs
It is known that human MoDCs change their molecular profile and immunological compliance in response to stimulation by TNFa or lipopolysaccharide. We evaluated the effect of NK026680 on the change in TNFa-induced protein expression of MoDCs. It was found that NK026680 inhibited the increase in expression of CD83, CD86 and MHC class II as well as MHC class I antigens in a dose-dependent manner (Figure 2 ). In contrast, there was little effect on the increase in expression of CD1a, CD40 and CD54 (data not shown). Toxic effects of NK026680 on MoDC in our culture condition were evident at the highest concentration (200 nM) (Figure 3 ). NK026680 significantly suppressed the production of IL-12p40 in a dose-dependent manner (Figure 4 ).
Suppressive effect of NK026680 on allogeneic T-cell responses
Human T cells and mature MoDCs prepared from different volunteers were cocultured to induce an allogeneic T-cell response. NK026680 significantly suppressed the proliferation of human allogeneic T cells in a dose-dependent manner (IC 50 ¼ 15 nM) (Figure 5a ). However, it suppressed the CD3-and CD28-mediated T-cell response to a much lesser extent (IC 50 ¼ 427 nM), under conditions where T cells proliferate independently of DC function (Figure 5b ). Figure 6 ). These findings indicate that NK026680 suppresses T-cell activation in both MHC class I-and class II-dependent reactions.
Preventive effect of NK026680 on lethal acute GVHD in mice Next, we tested the efficacy of NK026680 in mouse acute GVHD models. Two kinds of recipient mice, (B6 Â bm1) F 1 or (B6 Â bm12) F 1 , were used to develop CD8T-celldependent acute GVHD (CD8-GVHD) or CD4T-celldependent acute GVHD (CD4-GVHD), respectively. 5, 6 CD4 or CD8T cells were prepared from B6 splenocytes with anti-CD4-or anti-CD8-conjugated magnetic beads, respectively. Each type of acute GVHD was induced by adaptive transfer of CD8 or CD4T cells to irradiated recipient mice. Recipient survival and body weight change were monitored as measures of acute GVHD onset by at least the 55th day post transplantation (Figures 7 and 8) . In CD8-GVHD, the median survival time of recipient mice treated with vehicle, low-dose NK026680 (5 mg/kg once daily p.o. from day À1 to 18, total dose 100 mg/kg), highdose NK026680 (20 mg/kg once daily p.o. on day À1 to 18, total dose 400 mg/kg) or CsA (50 mg/kg once daily p.o. from day À1 to 12, total dose 700 mg/kg) was 18, 23.5, 76 and 15 days, respectively. The difference in the rate of survival between the NK026680-treated groups and the control group was statistically significant (Figure 7a ). NK026680 significantly suppressed body weight loss in CD8-GVHD (Figure 8a ). In CD4-GVHD, the median survival time of recipient mice treated with vehicle, lowdose or high-dose NK026680, or CsA was 21.5, 23, 55 and 21 days, respectively. The difference in the rate of survival between the group treated with high-dose NK026680 and the control group was statistically significant (Figure 7b ). NK026680 significantly suppressed body weight loss in CD4-GVHD (Figure 8b) .
We investigated the most efficacious time schedule of administration for acute GVHD therapy. Schedules were varied under the high-dose administration (20 mg/kg once daily p.o.) in CD8-GVHD. The preventive (days À1 and 0) and early interventive (days 0-1) schedules significantly improved survival (Table 1) . With a prolonged period of administration, the therapeutic effect of NK026680 was more prominent. There was no significant difference in median survival time between the two schedules of longterm administration (20 days from day À1 to 18, and 18 days from day 1 to day 18). Notably, the delayed schedule (from day 4 to day 18) failed to improve recipient survival. These findings show that an early event in CD8-GVHD is a target of action of NK026680.
Discussion
DCs play important roles in immune responses by presenting antigen (Signal-1) with accessory signaling (Signal-2) and cytokine stimulation for T cells. 14, 15 DCs A new DC inhibitor NK026680 suppresses acute GVHD K Saiga et al are further involved in a variety of immunological disorders, including acute GVHD and acute graft rejection in transplantation, and probably autoimmune diseases.
1,2,16-18 Thus, it has been proposed that immunological disorders can be controlled by suppressing DC functions. In this respect, we have long attempted to develop a pharmacological approach to suppress DC function with a newly synthetic chemical compound. Among a large number of compounds screened, NK026680 was eventually characterized as the most potent suppression of TNFa-induced MHC class I augmentation on human MoDCs. Our data indicate that NK026680 suppresses the expression of not only MHC class I, but also MHC class II, IL-12 and other effector molecules associated with DC functions in human MoDCs. It is of note that this suppressive effect is especially profound in the excretion of IL-12, which has been characterized as a key cytokine for allogeneic T-cell responses. 19, 20 The impact on IL-12 excretion may significantly contribute to the beneficial effect of NK026680 in vivo.
Data in Table 1 are indicative of the mode of action of NK026680 in vivo. Three short-term schedules of NK026680 administration (from day À1 to day 0, day 3 or day 8) were significantly effective on recipient survival in the CD8-GVHD model (Table 1 ). In contrast, the delayed long-term schedule (from day 4 to day 14) was not effective at all. Previous studies have demonstrated that donor T cells start to proliferate in host lymphoid tissues such as Peyer's patches and spleen by the third day of transplantation. 21, 22 It is possible that NK026680 preferentially affects such early T-cell proliferation in the CD8-GVHD model by suppressing host DC function. Furthermore, it was proven that the beneficial effect increased depending on the period of NK026680 administration. These findings may suggest two targets of NK026680 action in the CD8-GVHD model. The first target is an early event that takes place within the initial 3 days after transplantation. The second target is a delayed event whose onset depends on the early event and less on the DC function developed in the late stage. Successful intervention regarding the first target may be prerequisite to the prophylaxis of acute GVHD using NK026680.
When compared to established immunosuppressive drugs, NK026680 is unique in chemical structure and belongs to the [1, 2, 4] triazolo [1,5-a] pyrimidines (Figure 1) . Derivatives similar to NK026680 also have immunosuppressive activity, but to a lesser extent. Three derivatives of triazolo-pyrimidine are used as an A3 adenosine receptor antagonist, anti-hypertension drug and herbicidal agent. We proved that these three derivatives had no effect on the expression of MHC class I on human MoDCs (data not shown). Our preliminary study showed that NK026680 significantly suppressed primary antibody production revealed by plaque forming assay and footpad delayed It is not fully addressed whether NK028860 directly affects T-cell activation. The present data showed weak suppression of CD3/CD28-mediated human T-cell response at a high dose of NK026680 ( Figure 5 ). It is known that plate-bound antibodies to CD3 and CD28 activate a T-cell response without the help of DCs. The weak suppression may be due to a direct or an indirect (cytotoxic) effect of NK026680 on T cells. The present data do not exclude either of the possible effects. However, one can conclude that NK026680 mainly suppresses DCs.
We observed a toxic effect of NK026680 on MoDCs in the culture at a high concentration (200 nM), whereas there was little proven toxic effect of NK026680 at moderate concentrations, even though they were suppressive of other biological responses (Figures 2, 4 and 5a) . Considering the maximal plasma concentration (C max ¼ 1280 nM) of NK026680 after the treatment with a single dose of 3 mg/kg p.o., the toxic effect in the culture at 200 nM should be taken into account. As no remarkable toxic effect has been observed in mice or dogs, we speculate that there is a difference in toxic sensitivity between in vivo and in vitro conditions, or among cell types. The toxicological properties of NK026680 are now being investigated.
Our demonstrations in vivo proved the efficacy of oral and time-limited administrations in acute GVHD models. This availability may be beneficial to clinical use and allow combined use of NK026680 with established immunosuppressants.
